← All organizations
Kyowa Kirin
Also known as: Kirin Holdings Company, Limited | Kyowa Kirin | KYOWA KIRIN | Kyowa Kirin, Inc. | Kyowa Kirin Korea Co., Ltd. | Kyowa Kirin Pharmaceutical Development, Inc. | Kyowa Kirin Pharmaceutical International Ltd. | Orchard Therapeutics (Europe) Ltd.
Highest phase reached
Phase 3
First clinical trial
Mar 1, 2002First marketed drug
May 29, 1997First NDA
May 29, 1997Last known activity
Jul 31, 2025
Timeline
1940s
- Jan 1, 1949
Kyowa Kirin— Founded
2000s
- Sep 12, 2008
granisetron— NDA Secondary Org
2010s
- Apr 17, 2018
burosumab-twza— Marketing Organization
2020s
- Oct 5, 2023
Orchard Therapeutics Limited— Acquired
- Mar 18, 2024
Atidarsagene autotemcel— NDA Organization
Drugs by trial phase (28 distinct, 30 trials)
Phase 3 (10 own, 4 via acquisition)
Phase 2 (4 own, 3 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Transitional Cell
- Dermatitis
- Dermatitis, Atopic
- Eczema
- Familial Hypophosphatemic Rickets
- Gastroparesis
- Hypophosphatemia
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liver Diseases
- Lung Neoplasms
- Movement Disorders
- Myelodysplastic Syndromes
- Parasomnias
- Parkinson Disease
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Psychomotor Agitation
- Purpura, Thrombocytopenic, Idiopathic
- Restless Legs Syndrome
- Sleep Wake Disorders
- Syndrome
- Thrombocytopenia
Marketed drugs (6)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (29)
- NCT04321694Lead sponsorN/A—
- NCT07089238Lead sponsorN/AJul 31, 2025
- NCT06837961OfficialPhase 3Apr 29, 2025
- NCT06837961CollaboratorPhase 3Apr 29, 2025
- NCT06827327OfficialPhase 3Mar 28, 2025
- NCT06827327CollaboratorPhase 3Mar 28, 2025
- NCT06906848Lead sponsorN/ANov 20, 2024
- NCT04695860CollaboratorPhase 3Dec 31, 2021
- NCT04967157Lead sponsorN/ASep 8, 2021
- NCT04745832CollaboratorPhase 3Apr 1, 2021
- NCT04289207CollaboratorPhase 2Mar 1, 2020
- NCT04190654Study directorPhase 1Nov 26, 2019
- NCT04190654Lead sponsorPhase 1Nov 26, 2019
- NCT04147910Lead sponsorPhase 1Aug 21, 2019
- NCT04147910Study directorPhase 1Aug 21, 2019
Details
- Founded
- Tokyo, JP Jan 1, 1949
- First NDA
- May 29, 1997
- Last known activity
- Jul 31, 2025
Designations held
- Orphan drug
- Priority review
- Breakthrough therapy